The effect of intravenous magnesium sulfate as a complementary therapy to COPD

Study of the effect of intravenous magnesium sulfate on clinical performance as a complementary therapy of the patients with COPD in the emergency department

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150315021480N8

Enrollment

100

Registered

2018-05-09

Start date

2017-10-23

Completion date

Unknown

Last updated

2018-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic obstructive pulmonary disease. j44

Interventions

Intervention 1: Intervention group: Magnesium sulfate (2%) Obiidi pharmaceutical company is mixed with 200 ml of normal saline and is given intravenous infusion intravenously in 20 minutes. Interventi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients with chronic pulmonary obstruction with moderate severity.

Exclusion criteria

Exclusion criteria: Patients who have the need for intubation. Patients who have a history of heart disease Patients who have a low level of consciousness Patients who received intravenous magnesium sulfate within the last 24 hours

Design outcomes

Primary

Measure	Time frame
Number of breaths. Timepoint: Counting the number of breaths at the beginning of the study (before the intervention) and 45 minutes and 6 hours after starting magnesium sulfate. Method of measurement: We count the breath per one minute.	—

Secondary

Measure	Time frame
Blood pressure. Timepoint: before intervention and 45 minutes and 6 hours after intervention. Method of measurement: We get blood pressure using a manometer portable .	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSepideh Amirifar

Mazandaran University of Medical Sciences

sepidehamirifard@gmail.com+91 11555084

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026